Valuation: Biocon Limited

Market Cap 709B 7.35B 6.44B 5.98B 5.49B 10.35B 10.51B 71.23B 27.88B 347B 27.59B 27B 1,199B P/E 2027 *
52.2x
P/E 2028 * 35x
Enterprise Value 814B 8.43B 7.39B 6.86B 6.3B 11.88B 12.05B 81.73B 31.99B 398B 31.66B 30.98B 1,376B EV / Sales 2027 *
4.07x
EV / Sales 2028 * 3.5x
Free-Float
46.2%
Yield 2027 *
0.15%
Yield 2028 * 0.21%
1 day-0.53%
1 week+0.15%
Current month+4.70%
1 month+5.40%
3 months+21.15%
6 months+20.04%
Current year+11.18%
1 week 426.35
Extreme 426.35
447.15
1 month 394.85
Extreme 394.85
447.15
Current year 337.7
Extreme 337.7
447.15
1 year 331
Extreme 331
447.15
3 years 217.5
Extreme 217.5
447.15
5 years 191.55
Extreme 191.55
447.15
10 years 132.51
Extreme 132.5083
487.75
Manager TitleAgeSince
Investor Relations Contact - -
Chief Executive Officer - 31/03/2026
Director of Finance/CFO 48 31/03/2026
Director TitleAgeSince
Director/Board Member 71 31/12/1999
Chairman 73 28/11/1978
Director/Board Member 62 26/07/2018
Change 5-day change 1-year change 3-year change Capi.($)
-0.53%+0.15%+10.97%+65.92% 7.4B
-0.43%-1.26%+52.13%+85.69% 55.57B
-0.24%+1.04%+55.76%+58.36% 54.26B
-0.59%-0.11%-17.55%-14.15% 23.35B
-1.68%-2.94%+3.56%+420.92% 23.54B
+0.05%+1.68%+38.71%-4.57% 20.32B
+3.16%+0.79%+37.98%-29.06% 17.36B
+1.08%+3.77%+36.92%+593.96% 15.59B
+0.43%-1.67%+166.53%+299.61% 14.96B
-1.46%-0.43%+24.38%+178.08% 14.11B
Average -0.02%-0.14%+40.94%+165.48% 24.65B
Weighted average by Cap. -0.15%-0.21%+42.74%+136.55%

Financials

2027 *2028 *
Net sales 200B 2.07B 1.82B 1.69B 1.55B 2.92B 2.96B 20.09B 7.86B 97.9B 7.78B 7.62B 338B 229B 2.37B 2.08B 1.93B 1.77B 3.34B 3.39B 22.98B 8.99B 112B 8.9B 8.71B 387B
Net income 13.22B 137M 120M 111M 102M 193M 196M 1.33B 520M 6.47B 514M 503M 22.35B 20.24B 210M 184M 171M 157M 295M 300M 2.03B 796M 9.91B 788M 771M 34.22B
Net Debt 105B 1.08B 950M 882M 810M 1.53B 1.55B 10.51B 4.11B 51.2B 4.07B 3.98B 177B 91.37B 947M 830M 770M 708M 1.33B 1.35B 9.18B 3.59B 44.71B 3.55B 3.48B 154B
Logo Biocon Limited
Biocon Limited is an India-based biopharmaceutical company, engaged in the manufacture of biotechnology products and research services. The Company is in the business of manufacturing active pharmaceutical ingredients (APIs) and formulations, including biosimilar drugs for diabetics, oncology and autoimmune diseases. The Company’s segment includes Generics, Biosimilars, Novel Biologics and Research Services. It focuses on three key therapeutic areas - Oncology, Diabetes, and Immunology. Its APIs portfolio includes cardiovascular, anti-diabetics, immunosuppressants, and specialty molecules. Its products include Tacrolimus, Rosuvastatin, Simvastatin, Atorvastatin, Pravastatin, Fingolimod and others. Its APIs manufacturing facilities with capabilities in microbial fermentation, downstream process, including chromatographic purification, chemical synthesis, peptide synthesis and Highly Potent APIs (HPAPIs). It has over five facilities in Bangalore, Hyderabad and Visakhapatnam in India.
Employees
16,447
Date Price Change Volume
22/07/26 437.95 -0.53% 6,102,889
21/07/26 ₹440.30 +0.87% 3,318,862
20/07/26 ₹436.50 -0.16% 3,615,759
17/07/26 ₹437.20 -0.79% 8,811,391
16/07/26 ₹440.70 +1.40% 7,716,191
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
437.95INR
Average target price
423.70INR
Spread / Average Target
-3.25%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BIOCON Stock